Analyst Price Targets — APLS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 17, 2026 9:18 am | — | Wells Fargo | $41.00 | $40.87 | TheFly | Apellis downgraded to Equal Weight from Overweight at Wells Fargo |
| January 27, 2026 9:23 pm | — | Barclays | $24.00 | $21.81 | TheFly | Apellis initiated with an Equal Weight at Barclays |
| January 20, 2026 11:06 am | — | Wells Fargo | $26.00 | $19.94 | TheFly | Apellis price target lowered to $26 from $29 at Wells Fargo |
| January 13, 2026 12:54 pm | — | Cantor Fitzgerald | $35.00 | $23.20 | TheFly | Apellis price target lowered to $35 from $39 at Cantor Fitzgerald |
| January 12, 2026 6:45 pm | — | Goldman Sachs | $19.00 | $23.20 | StreetInsider | Goldman Sachs on Apellis Pharmaceuticals (APLS): 'we see limited near-term growth levers' |
| December 19, 2025 12:47 pm | — | Stifel Nicolaus | $48.00 | $24.48 | TheFly | Apellis price target lowered to $48 from $55 at Stifel |
| November 3, 2025 11:36 am | Graig Suvannavejh | Mizuho Securities | $19.00 | $21.47 | StreetInsider | Apellis Pharmaceuticals (APLS) PT Lowered to $19 at Mizuho |
| October 31, 2025 11:25 am | — | Robert W. Baird | $52.00 | $20.73 | TheFly | Apellis price target raised to $52 from $50 at Baird |
| October 31, 2025 10:05 am | — | H.C. Wainwright | $45.00 | $20.73 | TheFly | Apellis price target lowered to $45 from $57 at H.C. Wainwright |
| October 29, 2025 12:46 pm | — | Mizuho Securities | $24.00 | $29.70 | TheFly | Apellis price target raised to $24 from $22 at Mizuho |
Latest News for APLS
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) have received an average recommendation of "Hold" from the twenty-three brokerages that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, seventeen have issued a hold recommendation and four have issued a buy recommendation on the
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen.
Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for APLS.
U.S. House Trading
No House trades found for APLS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.